7. Please describe in brief why it was not feasible to get feedback from all potential end users.
Was there any patient or public involvement in the guideline development? This is relevant because it is one of the AGREE criteria that patients/public should be involved in guideline development and their non-involvement should be listed as a limitation of the study.
8. Heading: end user adaptation: The first sentence needs a reference.
9. Knowledge exchange opportunities: A table listing the organizations involved and the range of professionals who provided feedback would be useful.
10. It might be useful to provide a table as a supplement which details the AGREE scores obtained by the included guidelines. Results:
11. Was stakeholder feedback also used for developing recommendations for smoking cessation pharmacotherapy? If not, then the paper should clearly mention in the beginning, that this paper discusses the stakeholder involvement in development of behavioral smoking cessation interventions.
12. The first paragraph of the results section can possibly be moved to methods. Discussion 13. "Appropriate use of these technologies/platforms remains an ongoing challenge to explore the utility of an online and iterative process for guideline development". Please provide a reference. 14. Page 21, line 10-20: Consider revising this long sentence. Conclusion 15. A summary of barriers and gaps and how they were addressed during the process will be useful. 
REVIEWER

GENERAL COMMENTS
The paper outlines the adoption of non-pharmacologic smoking cessation guidelines into the Canadian context using validated tools (the AGREE tool and the ADAPTE framework). It is well written although the results section could be improved.
The background section forms an excellent foundation for the paper. My reading is that the Guideline Development Group formulated the Guideline Summary Statements based upon the background work of Guideline Advisory Committee (GAC). Feedback and clinical context was provided by end-users, but the end-users input did not alter the Summary Statements.
If the latter statement is incorrect, the paper needs to clarify how any changes wer made to the Summary Statements. How were the "regional knowledge exchange brokers" identified? Were they individuals or groups? What was their background? What kind of infrastructure did they have? I ask these questions because replication of the kind of effort undertaken by the authors requires an understanding of necessary resources. The authors point out that Canada is a well-resourced country.
How was the "inter-professional network of over 800 members" established? What was their professional composition? Were these the attendants at the annual general meeting (AGM) workshops? What was the response rate to "engagement" efforts and was a minimum response or feedback rate required? Can we show that the engagement effort was a success or was it limited?
The Results section could be used to discuss actual rates of enduser engagement and feedback. Changes in the document resulting from engagement could be usefully shared. Can such examples be provided? Did the end product (Summary statements or other) look substantially different than the initial draft document? The referenced Cancer Care Ontario guideline process does allow for change in formal recommendations based on reviewer feedback.
In the Results section, the statement is made that "Adoption of the guideline was evident…" followed by examples. Some of the examples are certainly efforts at dissemination, such as "guideline was provided to…organizations" and "presentations were given" but those do not represent actual adoption. The list might therefore be paired down to stronger examples.
The literature search was conducted in January, 2009. Can the authors comment on the gap between 2009 and present in terms of potential guidelines and their implications for practice? The Discussion notes some uncertainty about the necessary frequency for guideline updates. If an update were to occur, could the authors comment on how extensive engagement should be during that process? Replicating the initial effort appears onerous.
An update on pharmacotherapy is mentioned for 2013 but is not referenced.
Minor comment:
This sentence took me a couple of reads to understand and might be broken up: This domain was identified by the GAC as critical to determining the quality of a CPG; for this reason the GAC process considered a 75% threshold when reviewing the AGREE scores, guidelines that do not score 75% are not generally considered high-quality and would therefore, for the purposes of this project, not be considered for use when developing the guideline.
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Ratika Sharma School of Public health, The University of Queensland, Australia
This paper describes the process of involving stakeholders in the development of behavioral recommendations included in a smoking cessation guideline in Canada.
Please find my comments below:
COMMENT 1. Overall, the paper is well written and describes the process of obtaining the end user feedback for developing the CAN-ADAPTT smoking cessation guidelines. However, the manuscript could be improved by a thorough proofreading.
RESPONSE:
The manuscript was thoroughly proof-read following revisions.
COMMENT 2. Please provide the full forms of the acronyms or abbreviations where they first appear in the text, e.g. "AGREE".
RESPONSE: We have reviewed the paper to ensure we have explained all abbreviations when they are first used. Please note that, to our knowledge, there is no full form for ADAPTE (http://www.g-in.net/working-groups/adaptation).
Methods: COMMENT 3. "Guidelines that received an overall AGREE rating of "strongly recommend" from at least three of the four reviewers, had a combined score of over 75% in the domain for rigor of development as well as most other domains"
How was most defined? Please specify what was the minimum number of domains which had to score 75% or above to be included.
We have revised this sentence on page 11 to specify that we selected guidelines with scores of at least 75% on the rigor of development domain in addition to 3 other domains (in total, 4 of 6).
COMMENT 4. Why 75% was considered a satisfactory percentage? Is this cut off provided in the original AGREE framework?
RESPONSE: AGREE does not set thresholds for the domain scores. The decision to set 75% as a cut off was a decision made by the GAC based on their expertise and years of experience with reviewing and endorsing guidelines. We have edited the section where appraisal of the guidelines is discussed (page 11, see under new heading "Appraisal of guidelines") to explain each of these points.
COMMENT 5. "One guideline which received two "strongly recommend" and two "recommend" overall ratings also scored over 75% in 5 of the 6 AGREE domains, and was also included for this reason." Please mention the name of this particular guideline.
We have now indicated which guideline this was on page 12 (the ICSI guideline for adults and mature adolescents).
COMMENT 6. "Each GDG member confirmed that they had not received funds from the Tobacco Industry". Was funding from pharma industry also taken into consideration, as it might also pose a significant conflict of interest when making recommendations for smoking cessation pharmacotherapy?
RESPONSE: This section (pages 12-13) has been edited to address how funding from the pharmaceutical industry was taken into consideration so as to minimize conflicts of interest during development of the recommendations.
COMMENT 7. Please describe in brief why it was not feasible to get feedback from all potential end users.
RESPONSE: The relevant sentence on page 13 has been edited to state that the feasibility was limited due to the large size of the group of potential end-users (combined with limited funding available as stated at the end of the next sentence).
COMMENT: Was there any patient or public involvement in the guideline development? This is relevant because it is one of the AGREE criteria that patients/public should be involved in guideline development and their non-involvement should be listed as a limitation of the study.
RESPONSE: There was no specific effort to seek input from patients or the public to prevent tokenism but the guideline website is freely available and anyone could have registered to provide feedback. We have added this limitation on page 27. However, we also note that HCPs and others that did provide input may themselves have been current or former smokers or family members of those who used tobacco. We did not collect these data to respect participant privacy.
COMMENT 8. Heading: end user adaptation: The first sentence needs a reference.
We have added citations to this sentence on page 14.
COMMENT 9. Knowledge exchange opportunities: A table listing the organizations involved and the range of professionals who provided feedback would be useful.
RESPONSE: While we did track information regarding professional background and organization for all network members at registration, feedback was not linked back to organization or professional group. On page 15 we have added a list of the healthcare professions represented in the CAN-ADAPTT network. The list of organizations the network members were a part of is also now presented in a supplementary table, and as it is quite long (>400 organizations) we leave it up the discretion of the editor whether to include it.
COMMENT 10. It might be useful to provide a table as a supplement which details the AGREE scores obtained by the included guidelines.
RESPONSE: We have added this table as a supplement (see Supplementary Table 1) .
Results COMMENT 11. Was stakeholder feedback also used for developing recommendations for smoking cessation pharmacotherapy? If not, then the paper should clearly mention in the beginning, that this paper discusses the stakeholder involvement in development of behavioral smoking cessation interventions.
RESPONSE: At the top of page 19 we clarify that the separate pharmacotherapy section where specific medications were graded (not covered in this paper) was developed with prescribers alone. The guideline version and process described in this paper did include broad recommendations regarding pharmacotherapy as a topic in addition to behavioral interventions. Stakeholder feedback was sought on these recommendations and incorporated in the clinical considerations sections. We have clarified this in the manuscript COMMENT 12. The first paragraph of the results section can possibly be moved to methods.
RESPONSE: The first paragraph of the results describes the product (the guideline) that resulted from the methods described and therefore we felt it most appropriate to remain in the Results section. However, to better separate the methods from results we moved Table 3 (summary statements) to the Results section. Discussion COMMENT 13. "Appropriate use of these technologies/platforms remains an ongoing challenge to explore the utility of an online and iterative process for guideline development". Please provide a reference.
RESPONSE: We have rephrased this sentence on page 25 with the intention to make clearer that based on the challenge we experienced, further investigation is needed (therefore there is no reference).
COMMENT 14. Page 21, line 10-20: Consider revising this long sentence.
We have decreased the length of this sentence (which is now on page 24).
Conclusion 15. A summary of barriers and gaps and how they were addressed during the process will be useful.
We have extended this section on page 24 to list some of the needs and gaps that were identified and how they were addressed.
Reviewer: 2
John Goffin MD FRCPC Juravinski Cancer Centre at McMaster University. Hamilton, Ontario, Canada
The background section forms an excellent foundation for the paper.
COMMENT: My reading is that the Guideline Development Group formulated the Guideline Summary Statements based upon the background work of Guideline Advisory Committee (GAC). Feedback and clinical context was provided by end-users, but the end-users input did not alter the Summary Statements. If the latter statement is incorrect, the paper needs to clarify how any changes were made to the Summary Statements.
RESPONSE: This is correct, the summary statements were not altered based on end-user input.
COMMENT: How were the "regional knowledge exchange brokers" identified? Were they individuals or groups? What was their background? What kind of infrastructure did they have? I ask these questions because replication of the kind of effort undertaken by the authors requires an understanding of necessary resources. The authors point out that Canada is a well-resourced country.
RESPONSE: We have edited this section on page 16 to explain how regional knowledge exchange brokers were hired and describe their background and the infrastructure available to them.
COMMENT: How was the "inter-professional network of over 800 members" established? What was their professional composition? Were these the attendants at the annual general meeting (AGM) workshops?
RESPONSE: Strategies used to recruit members and data regarding professional composition of the network have been added to the "CAN-ADAPTT network" section on pages 14-15. We have also added a sentence on page 16 to outline who was invited to the AGMs.
COMMENT: What was the response rate to "engagement" efforts and was a minimum response or feedback rate required? Can we show that the engagement effort was a success or was it limited? RESPONSE: We are not able to report a response or feedback rate as we do not know what the denominator was given that the opportunity to provide feedback was not limited to network members and many various strategies to engage end-users were used (e.g., invitations to AGMs were widely circulated to an unknown number of individuals). A convenience sample was used and there was no minimum response rate. Since this was a new process we could not compare it to similar projects in order to judge the degree of success. Success of engagement efforts is also determined by quality of the feedback received, which is difficult to quantify and evaluate. We have added a sentence to the Limitations on page 27 of the Discussion to mention the difficulty of judging the success of our engagement efforts.
COMMENT: The Results section could be used to discuss actual rates of end-user engagement and feedback. Changes in the document resulting from engagement could be usefully shared. (Table 4) to give examples of the clinical considerations that were added to the guideline after the GDG reviewed the summary statements made by the GAC. These considerations capture the end-user feedback provided. As described above, summary statements did not change based on enduser feedback to respect the evidence-based recommendations.
COMMENT: In the Results section, the statement is made that "Adoption of the guideline was evident…" followed by examples. Some of the examples are certainly efforts at dissemination, such as "guideline was provided to…organizations" and "presentations were given" but those do not represent actual adoption. The list might therefore be paired down to stronger examples.
RESPONSE: We have edited this section on page 23 to differentiate between dissemination efforts and evidence of adoption of the guideline.
COMMENT: The literature search was conducted in January, 2009. Can the authors comment on the gap between 2009 and present in terms of potential guidelines and their implications for practice? The Discussion notes some uncertainty about the necessary frequency for guideline updates. If an update were to occur, could the authors comment on how extensive engagement should be during that process? Replicating the initial effort appears onerous.
RESPONSE: As the reviewer notes, we did mention there is an uncertainty in the literature regarding frequency of guideline updates. However, we have identified the need to update the pharmacotherapy section (since the previous 2012 version) and note that this is currently in progress and due for release in 2017. We also state that the other sections do not require as frequent updating given the robustness of evidence to date for screening and counselling. However, the questions raised by the reviewer are important ones and we have added several sentences to this section on pages 26-27 to further discuss the process of updating the guideline, including engagement by end-users.
COMMENT: An update on pharmacotherapy is mentioned for 2013 but is not referenced.
RESPONSE: We thank the reviewer for pointing out this omission, we have added a citation/reference to the 2012 version (2013 was an error) of the pharmacotherapy guideline.
Minor comment: This sentence took me a couple of reads to understand and might be broken up: This domain was identified by the GAC as critical to determining the quality of a CPG; for this reason the GAC process considered a 75% threshold when reviewing the AGREE scores, guidelines that do not score 75% are not generally considered high-quality and would therefore, for the purposes of this project, not be considered for use when developing the guideline.
RESPONSE: This sentence (bottom of page 11) has been revised to decrease length and improve clarity.
